The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | MRD in myeloma: the need for sensitive and standardized measures
Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, discusses the work conducted by a group formed to analyse the use of measurable residual disease (MRD) in the treatment of multiple myeloma. Dr Kirsch summarizes the key points from a paper put together by a consortium of academic, industry and government foundations which provided the background into the current status of MRD, regulatory considerations and the technologies involved. Dr Kirsch explains the valuable insights gained with the use of MRD, such as clinical status, response to therapy and tumour burden, and talks on the need for a highly accurate, sensitive, and standardized approach to measure outcomes. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Lanny Kirsch, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
